Cedar Gate analysis finds bariatric surgery down 13% as GLP-1 use climbs 67%

Bariatric surgery volume fell 13% over the past year while the number of members taking GLP-1 medications rose 67% over two years, according to an analysis from Cedar Gate Technologies, an IQVIA business ^[1]. The analysis, released Feb. 18, 2026, also compared costs, putting the average bariatric surgery at $24,215 in 2024 against roughly $5,200 a year per patient for GLP-1 prescriptions ^[1].

The two trends move in opposite directions, and Cedar Gate describes them as indicating a notable shift toward nonsurgical weight loss treatment ^[1]. The figures are measured over different windows — one year for surgery volume, two years for GLP-1 use — so they are not a like-for-like comparison ^[1]. The release also carries a caveat in its own framing: long-term benefits remain unclear ^[1].

On cost, the analysis found the average bariatric surgery cost $24,215 in 2024, a 9.62% increase over the prior year ^[1]. The average annual cost per patient for GLP-1 prescriptions was approximately $5,200, up 8.33% from 2023 ^[1]. The cost figures cover one year of GLP-1 prescriptions against a one-time surgery, and the analysis does not report the cost of taking a GLP-1 for multiple years ^[1].

The release does not break down how those costs are divided among insurers, employers and patients, and it does not say whether the GLP-1 figure reflects list price, a negotiated price after rebates, or the amount actually paid at the pharmacy counter ^[1]. That split has not been disclosed.

The analysis is based on Cedar Gate's data on members. It does not report how many members were studied, which health plans or employers are included, which regions are covered, or which specific GLP-1 drugs patients took ^[1]. It also does not follow individual patients, so it does not show that any particular person who would otherwise have had surgery took a GLP-1 instead ^[1]. The relationship shown is between two population-level trends, not a patient-by-patient swap.

Why it matters for patients

The cost comparison is the part most likely to reach people deciding between the two options. Surgery is a single large expense that also carries recovery time, while GLP-1 drugs are an ongoing prescription whose cost repeats every month for as long as someone keeps taking them ^[1]. A one-year figure of about $5,200 looks lower than $24,215, but the analysis does not say what happens to that bill in year two, three or five, and it does not say what share of either cost lands on the patient rather than an insurer or employer ^[1].

The 13% decline in surgery volume also matters for access. If fewer procedures are being scheduled, the number of patients moving through bariatric surgery programs may be changing too, though the analysis does not report on program capacity, waiting times or which patients are being steered away from surgery ^[1]. It also does not say whether the people not having surgery are the same people starting GLP-1 prescriptions, or whether those are two separate groups whose numbers happen to be moving at the same time ^[1].

Coverage rules are another open question. The analysis does not report which plans cover GLP-1 drugs for weight loss, which require prior authorization, or which still cover bariatric surgery and under what conditions ^[1]. Those details shape what is realistically available to any one patient, and they are not part of this data.

What happens next

No follow-up study or updated figures have been announced, and the analysis does not project where either trend goes ^[1]. Whether the surgery decline continues, whether GLP-1 use keeps climbing at the same pace, and how the cost gap changes have not been reported ^[1].